Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2022-09-29 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于公司首次公开发行股票并在创业板上市之发行保荐工作报告
Audit Report / Information Classification · 95% confidence The document is titled as an "发行保荐工作报告" which translates to "Sponsorship Work Report" related to the initial public offering (IPO) and listing of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. on the Growth Enterprise Market (创业板). It is issued by CITIC Securities as the sponsor and lead underwriter. The content includes detailed descriptions of the project operation process, internal review procedures, due diligence, and regulatory compliance related to the IPO process. This type of document is a detailed report prepared by the sponsor for the IPO process, which is distinct from an annual report or earnings release. It is not a simple announcement or certification but a comprehensive work report on the sponsorship and underwriting activities for the IPO. This fits the category of an Audit Report / Information (AR) because it is a standalone report related to regulatory compliance, due diligence, and audit-like review activities for the IPO, excluding full annual reports or financial statements. The document length (15,000 characters) and detailed content confirm it is a full report, not just an announcement or certification. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2021
2022-09-29 Chinese
上海泓博智源医药股份有限公司首次公开发行股票并在创业板上市招股意向书
Regulatory Filings Classification · 95% confidence The document is titled as a 招股意向书, which translates to a "Prospectus" or "Offering Intention Document" related to an initial public offering (IPO) and listing on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It contains detailed information about the stock issuance, risk factors, company business, financial data, governance, and other disclosures typical of an IPO prospectus. It is not an annual report, earnings release, or any other report type listed. The document is comprehensive and lengthy (15,000 characters), containing substantive financial and business information, not merely an announcement or certification. Therefore, it fits best into the category of a Prospectus or Offering Document, which is not explicitly listed in the provided categories. However, the closest and most appropriate category for IPO prospectuses and offering documents is "Regulatory Filings (RNS)" as a fallback for miscellaneous filings that do not neatly fit into other categories. Hence, the classification is RNS with high confidence.
2022-09-29 Chinese
中信证券股份有限公司关于公司首次公开发行股票并在创业板上市之发行保荐书
Regulatory Filings Classification · 95% confidence The document is titled as an "发行保荐书" (Sponsorship Letter) related to the initial public offering (IPO) and listing of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. on the ChiNext board. It contains detailed information about the sponsor (CITIC Securities), the issuer, legal and regulatory compliance, due diligence, risk factors, and the sponsor's conclusion supporting the IPO. The document is comprehensive and exceeds 15,000 characters, indicating it is a full report rather than a brief announcement. It is not an annual report, earnings release, or other financial report but a formal sponsorship document required for IPOs in China, which is a type of regulatory filing related to capital markets and securities issuance. Given the detailed nature and regulatory context, this document fits best under the category of Regulatory Filings (RNS), as it does not match other categories like Capital/Financing Update (CAP) or Proxy Solicitation (PSI).
2022-09-29 Chinese
上海泓博智源医药股份有限公司首次公开发行股票并在创业板上市提示公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It includes information about the approval by regulatory bodies (Shenzhen Stock Exchange and China Securities Regulatory Commission), the issuance process, subscription dates, pricing, investor qualifications, allotment, and other procedural details related to the IPO. It is not a financial report, earnings release, or management discussion but rather a formal announcement about the capital raising event and stock issuance. The document is lengthy (over 7,000 characters) and contains detailed procedural and regulatory information about the stock issuance and listing on the Growth Enterprise Market (创业板). Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-09-29 Chinese
经注册会计师鉴证的非经常性损益明细表
Regulatory Filings
2022-09-29 Chinese
发行人控股股东、实际控制人对招股说明书的确认意见
Regulatory Filings Classification · 95% confidence The document is a confirmation opinion from the controlling shareholder and actual controller regarding the prospectus for the company's initial public offering (IPO) on the Growth Enterprise Market (创业板). It is a statement confirming the accuracy and completeness of the prospectus content related to the controlling shareholders. This is not a financial report, audit, or earnings release, nor is it a voting result or management change announcement. It is a regulatory filing related to the IPO process but does not fit into categories like 10-K, IR, or CAP. Given the nature and length (653 characters), it is a regulatory filing (RNS) as it is a formal confirmation statement related to regulatory compliance and disclosure. Confidence is high due to clear identification of document purpose and content.
2022-09-29 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.